Cardiovascular biotech Regado Biosciences sets terms for $75 million IPO

By
A A A

Regado Biosciences, which is focused on the discovery and development of drugs for cardiovascular indications, announced terms for its IPO on Friday. The Basking Ridge, NJ-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Regado Biosciences would command a fully diluted market value of $219 million. Regado Biosciences, which was founded in 2001, plans to list on the NASDAQ under the symbol RGDO. Regado Biosciences initially filed confidentially on March 1, 2013. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: RGDO

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

95,530,319
  • $15.15 ▼ 1.81%
88,891,852
  • $6.01 ▼ 6.09%
80,331,117
  • $117.16 ▼ 1.46%
75,474,903
  • $40.40 ▼ 3.83%
58,037,145
  • $3.54 ▲ 18.39%
53,961,231
  • $32.92 ▼ 0.12%
51,698,455
  • $23.89 ▼ 0.79%
41,667,475
  • $3.55 ▼ 1.11%
As of 1/30/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com